We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · August 06, 2020

Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients With HR+/HER2− Breast Cancer

The Oncologist

 

Additional Info

The Oncologist
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer
Oncologist 2020 Jul 03;[EPub Ahead of Print], F Miglietta, MV Dieci, V Tsvetkova, G Griguolo, G Vernaci, A Menichetti, G Faggioni, T Giarratano, E Mioranza, E Genovesi, E Cumerlato, M Bottosso, T Saibene, S Michieletto, M Lo Mele, P Conte, V Guarneri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading